Viatris Views Ophthalmology, Dermatology, and Gastroenterology as Future Pipeline Focus

Equity Analyst

Keonhee Kim

Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris is one of the largest generic drug manufacturers in the world. Viatris' generics business makes up roughly 40% of company's sales and, along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin 

headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. 

Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Viatris. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

The remaining 60% of Viatris’ sales is derived from off-patent branded drugs, including Lipitor, Lyrica, and Norvasc. While macrotrends like the aging population and growing emerging markets can continue to boost sales, we still expect low- to mid-single-digit erosion in the business from pricing and volume headwinds driven from more patients opting generic versions. To combat this, Viatris has identified ophthalmology, dermatology, and gastroenterology as three key therapeutic areas of focus for future innovations. Since these areas are all specialty-driven, a small salesforce can capture a large number of doctors. And a lot of innovations usually come from smaller players, meaning there is not one big leader that Viatris has to displace to gain shares. It launched Tyrvaya, the first and only nasal spray 

for the treatment of dry eye disease at the time of launch, and it expects additional products for dry eye disease going forward. In 2023, it acquired Oyster Point and Famy Life Sciences, two companies that focus on ophthalmology, and we expect additional small tuck-in acquisitions in the three therapeutic areas to fuel its pipeline.

Business Strategy & Outlook

We assign Viatris a no-moat rating because we do not believe the company possesses any structural advantages strong enough to earn excess returns and generate return on invested capital above its cost of capital over the next 10 years. 

While generic drugs were around in the U.S. since the early 20th century, their industry experienced a significant growth following the passage of the 1984 Hatch-Waxman Act. The legislation facilitated the drug application process for generic drug manufacturers by providing them a safe harbor from patent infringement litigation from branded drug manufacturers and allowed the U.S. Food and Drug Administration to approve applications for generic drugs with abbreviated new drug applications. An ANDA requires the applicant to demonstrate its generic drug’s pharmaceutical equivalence and bioequivalence to the reference drug, but it generally does not require preclinical and clinical data to prove safety and effectiveness since it relies on the FDA’s prior approval of the reference drug’s safety and effectiveness. Overall, this legislation paved a much swifter way for generics manufacturers to get their drugs approved compared with a new drug application, which a new branded drug must go through.

The U.S. generic drug industry enjoyed another boost when Congress enacted a series of amendments named the Generic Drug User Fee Amendments (first one passed in 2012, second in 2017 and the latest in 2022), allowing the FDA to collect fees from ANDA applicants to expedite application approval process. The fees (an ANDA fee rate for 2023 was around $240,000) are not meaningful to sway big generic manufacturers away and they also provide additional revenue streams and financial support to the FDA, allowing applications to be approved more quickly and efficiently. 

These regulatory pushes by the U.S. government paved ways for the industry to be highly competitive and be filled with commoditized products, eroding a lot of pricing power that generics manufacturers once had. And although there are a few number of players that make up a relatively healthy share of the generics market, barriers to entry here is quite low, expanding possibilities for firms in the space to face additional competition going forward. This explains the hike in generic dispensing rate (percentage of prescriptions dispensed with a generic rather than a branded reference drug) which grew from 54% to 91% between 2002 and 2019. And while an average of less than 300 ANDAs were approved annually from 1985 to 2012, thanks to these changes, the FDA has averaged around 1,000 ANDA approvals per year over the last five years. 

Beyond government actions, generics manufacturers also face pressures from players within the drug supply chain. The formation of powerful generic sourcing groups and establishment of generic formularies by pharmacy benefit manager enabled drug distributors and drug buyers to effectively negotiate lower generic prices, hurting manufacturers’ margins.

Three large generic sourcing programs that were formed as joint ventures between large wholesalers and drug purchasers—ClarusONE (2016, McKesson and Walmart); Red Oak Sourcing (2013, Cardinal Health and CVS); and Walgreens Boots Alliance Development (2012, AmerisourceBergen and Walgreens)—have acted as additional headwind for generics manufacturers. These entities were created to lower generics acquisition costs through the aggregation of purchasing power and as a result, they can demand higher buy-side discounts and rebates from generics manufacturers, ultimately eating into their profits. They now purchase roughly 80% of all generics sold in the U.S. Additionally, the interchangeability between generics has facilitated the establishment of generic formularies, in which wholesalers can use their purchasing scale to negotiate deeper concessions for placement in the generic sourcing program. As these three players continue to make up a larger portion of generic sourcing in the country and enhance their buying power, generics manufacturers are left with no other choice but to face the burden, resulting in low- to mid-single-digit price erosion in the market year over year.

By our estimate, roughly 40% and 50% of Viatris total sales are derived from generics and off-patent branded drugs, respectively, and both areas are highly susceptible to all the pricing headwinds mentioned above. Viatris has decided to combat this by rationalizing and optimizing its portfolio, carefully deciding which drugs to continue commercializing and which drugs to discontinue. The company opted to exit spaces where it had too many existing players and discontinue small-molecule drugs that are fairly simple to be FDA-approved and to be replicated. Furthermore, Viatris has continued to pursue more opportunities into branded drugs, aiming to launch sizable novel drugs that can have a meaningful impact on the top and bottom lines. Viatris has also sought to expand its presence in complex generics. These drugs typically face limited competition due to a more complicated level of research and development required before reaching commercial stage. Instead of being available in simple oral tablets, which are relatively easy to replicate by competitors, complex generics and biosimilars usually come in injectables, inhalers, and other different forms that pose more challenges to other manufacturers to produce. 

Despite these efforts, we don’t believe Viatris has any structural advantages over other generic manufacturers. It doesn’t have a meaningfully larger number of first-to-file launches compared with other players in the space. And even if it launches a few drugs that are first to market and gain 180-day exclusivity periods in certain products, they are likely to face direct competition as soon as that period expires, leading to significant volume reductions. If Viatris continues to downsize its portfolio of commoditized and easy-to-replicate generic drugs and replace them with more innovative medicines, we could potentially revisit our analysis. For now, we do not believe Viatris earns a moat rating.

None

Economic Moat

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prosecutors and regulators say Ramkumar Rayapureddy, global chief information officer, tipped a friend about a regulatory drug approval.

Viatris Executive Charged With Insider Trading

PITTSBURGH , Nov. 10, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it and Kindeva Drug Delivery L.P. have won a significant court decision in which the U.S. District Court for the Northern District of West Virginia found that AstraZeneca's Symbicort® patent, U.S. Patent No.

Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent

Hasbro

Paramount Global

Together, these stocks will ensure you're receiving a dividend each month of the year.

Want to Collect a High Dividend Every Month? Buy These 3 Stocks

Viatris' business is holding up better than expected, despite FX headwinds. A new path to growth clears visibility for investors as the company targets to be the next ophthalmology leader.

Viatris: A Spinoff That Got Even More Interesting

Oyster Point Pharma Inc

NEW YORK , Nov. 7, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oyster Point Pharma, Inc. ("Oyster Point" or the "Company") (NASDAQ: OYST), in connection with the proposed acquisition of the Company by Viatris Inc. (NASDAQ: VTRS) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $11.00 in cash for each share of Oyster Point common stock owned, plus a contingent value right ("CVR") representing the right to receive a potential cash payment of up to $2.00 per share.

SHAREHOLDER ALERT: Weiss Law Investigates Oyster Point Pharma, Inc.

Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.

Why Viatris (VTRS) Is Buying Oyster Point (OYST)

Viatris Inc. (NASDAQ:VTRS ) Q3 2022 Results Conference Call November 7, 2022 8:30 AM ET Company Participants Bill Szablewski - Head of Global Capital Markets Robert Coury - Executive Chairman Michael Goettler - Chief Executive Officer Rajiv Malik - President Dr. Jeff Nau - Oyster Point CEO Sanjeev Narula - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Umer Raffat - Evercore Chris Schott - JPMorgan Gary Nachman - BMO Capital Markets Ash Verma - UBS Jason Gerberry - Bank of America Glenn Santangelo - Jefferies Greg Fraser - Truist Securities Nathan Rich - Goldman Sachs David Amsellem - Piper Sandler Operator Good morning. My name is Gretchen, and I will be your conference operator today.

Viatris Inc. (VTRS) Q3 2022 Earnings Call Transcript

Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.

Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates

Investors are applauding a key step in Viatris' plans to return to growth.

Why Viatris Stock Is Jumping Today

Viatris Inc (NASDAQ: VTRS) shares are trading higher by 16.80% to $11.33 Monday morning after the company announced it will acquire Oyster Point Pharma. What Happened?

Why Viatris Shares Are Soaring Higher - Viatris (NASDAQ:VTRS)

Viatris (NASDAQ: VTRS ) issued a press release today with a slew of good news. For one thing, Viatris is acquiring two different businesses.

Viatris (VTRS) Stock Pops 17% on Acquisition News

Viatris (VTRS) delivered earnings and revenue surprises of 4.88% and 1.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) Q3 Earnings Beat Estimates

PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), today announced that it has entered into a definitive agreement under which Viatris Inc. (Nasdaq: VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of TYRVAYA ® (varenicline solution) Nasal Spray and Oyster Point Pharma's pipeline.

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris

Expects Biocon Biologics Transaction to Close Shortly Intends to Begin Executing on Stock Repurchase Program  Enters Agreements to Acquire Oyster Point Pharma and Famy Life Sciences for Aggregate of $700-$750 Million in Cash; Expects to Close in Q1 2023 Expects Combination of Acquisitions and Share Repurchases to be Accretive to Adjusted EPS in 2023 on a Standalone Basis Anticipates Acquisitions Will Have the Potential to Add at Least $1 Billion in Net Sales and at Least $500 Million in Adjusted EBITDA by 2028 Reaffirms Total Pre-Tax Proceeds Expected from Biocon Transaction and Certain Non-Core Asset Divestitures to be up to Approximately $9 Billion  Provides Financial Targets for 2024 to 2028, Including Top-Line Total Revenues CAGR of ~3%, Adjusted EBITDA CAGR of ~4-5%, and Adjusted EPS CAGR of ~Mid-Teens Reiterates Commitment to Maintaining its Investment Grade Rating; Continues to Expect to Fully Meet Phase 1 Financial Commitments by End of 2023, Including Reducing its Gross Leverage Ratio to Approximately 3x PITTSBURGH , Nov. 7, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences and that it will provide a strategic update on its February 2022 Investor Event in a conference call and live webcast today at 8:30 a.m. ET. Under the terms of a definitive agreement, Viatris has agreed to acquire Oyster Point for $11 per share in cash upfront through a tender offer.

Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event

Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange Headwinds and Absorbing Inflation Impact to Date Reports Total Revenues of $4.08 billion; U.S. GAAP Net Earnings of $354 million; Adjusted EBITDA of $1.50 billion; U.S. GAAP Net Cash Provided by Operating Activities of $869 million; and Free Cash Flow of $765 million Strong Year-to-Date Cash Flow; Approximately $2.81 billion of U.S. GAAP Net Cash Provided by Operating Activities and Approximately $2.56 billion in Free Cash Flow Meets Annual Target of Paying Down Approximately $2.1 billion of Debt Year to Date, One Quarter Ahead of Schedule Board of Directors Declares Quarterly Dividend of $0.12 Per Share [1] Viatris is not providing forward-looking guidance for U.S. GAAP net earnings (loss) or a quantitative reconciliation of its 2022 adjusted EBITDA guidance. U.S. GAAP net cash provided by operating activities for 2022 is estimated to be between $3.1 billion and $3.3 billion.

Viatris Reports Strong Third Quarter 2022 Results

GlaxoSmithKline

The Vanguard Health Care Fund (Trades, Portfolio) disclosed in a regulatory filing that its top trades during the third quarter included the closure of its positions in Viatris Inc. ( VTRS , Financial) and Universal Health Services ( UHS , Financial), a reduction to its holding in Vertex Pharmaceuticals Inc. ( VRTX , Financial), a new holding in GSK PLC ( LSE:GSK , Financial) and a boost to its holding in DexCom ( DXCM , Financial).

Vanguard Health Care Fund Exits Viatris, Plugs Into GSK in 3rd Quarter

In the latest quarter, ignoring the quite severe effects of the dollar's appreciation, Viatris' brands performed well. But even for biosimilars, Viatris is proving portfolio value in the sale of that portfolio for a more than 10x multiple.

Viatris Asset Disposals Make The Value Case For Their Branded Portfolio

Altria

V.F.

Verizon

As you can see, I nibbled on several different positions earlier this month. Seeing some of these dividend stalwarts with yields way above their historical average was too much to ignore. Sure prices may continue to fall further but as a long time dividend investor I know that it is impossible to catch an absolute bottom.

Recent Stock Purchase October 2022

PITTSBURGH , Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022. Executive Chairman Robert J.

Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022

Company rises to the top 10% of the 800 global employers included on the list PITTSBURGH , Oct. 11, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced that it has been named to Forbes' list of World's Best Employers 2022. Viatris has received this recognition in each of its first two years since launching in 2020 as a new company.

Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row

American Airlines

Ford Motor Company

Nokia

SoFi Technologies

Telefonica SA

Bulls and bears alike have always sought out cheap stocks to buy. Most investors just can't get enough, no matter what stage we're in.

Cheap Stocks to Buy Now if You Have $100 to Spend

Viatris Inc. (NASDAQ: VTRS) shares have weakened from $10.20 to $8.42 since September 12, 2022, and the current price stands at $8.74. The U.S. stock market remains under pressure, and going forward, it will be hypersensitive to any FED comments.

Should I invest in Viatris shares after the current dip?

Pfizer

The silver lining amid the market collapse is that every new dollar put to work today in dividend stocks comes with an automatic higher yield when compared to just a few weeks ago. First up, I'm thinking about adding to recent spin-off Viatris Inc.

October 2022 Stock Considerations

Kraft Heinz

These stocks are distributing dividends yielding more than 4%.

2 Dirt-Cheap Dividend Stocks Trading Below Their Book Values

We were cautious on Viatris as we felt the three headwinds we anticipated would lead to a guidance cut. We were partially correct on that outcome, but the stock still went lower despite holding the free cash flow outlook.

News for Viatris Stock (VTRS)